UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On May 14, 2026, Chemomab Therapeutics Ltd. (the “~~Company~~Registrant”) ~~hereby~~ ~~furnishes~~issued ~~the~~a ~~results~~press ofrelease ~~its~~titled ~~annual general shareholders meeting (the~~ “~~Meeting”),~~Chemomab ~~which~~Therapeutics ~~was~~Announces ~~scheduled~~First ~~for~~Quarter ~~April 28,~~ 2026 ~~and~~Financial ~~adjourned~~Results toand ~~May~~Provides 5,Corporate ~~2026~~Update”, ata copy ~~4:30~~of ~~p.m.~~which ~~(Israel~~is ~~time),~~furnished atas ~~Meitar~~Exhibit |99.1 ~~Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel~~herewith.

The financial information included in the consolidated balance sheets and consolidated statements of operations contained in the press release attached as Exhibit 99.1 to this Report on Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

AtEXHIBIT the Meeting, the Company’s shareholders voted upon and approved, by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association (the “Articles”), the following proposals: (i) the re-election of each of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors, (ii) the approval of the compensation policy for office holders and directors, (iii) the approval of an increase of the Company’s authorized share capital and to amend the Company’s Articles accordingly, and (iv) the re-appointment of Somekh Chaikin, a member firm of KPMG international, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026; all in accordance with the Company’s proxy statement related to the Meeting, which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on March 20, 2026.INDEX

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

Exhibit	Description

99.1	Press release, dated May 14, 2026, titled “Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: May 6, 2026	By:	/s/ Sigal Fattal
Date: May 14, 2026	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer

Filing Compare · Chemomab Therapeutics Ltd.